Clinical Trials Directory

Trials / Completed

CompletedNCT04761900

MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes

Metabolic Associated Fatty Liver Disease-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes in Real World

Status
Completed
Phase
Study type
Observational
Enrollment
3,372 (actual)
Sponsor
Ningbo No. 1 Hospital · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers

Summary

Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries.

Detailed description

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver diseases. It affects nearly 25% of the global population. Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis. It helps to increase patient awareness and understanding of fatty liver (FL), for who has high-risk metabolic dysfunction. However, a more simplified and easily applicable definition is needed. It will have an impact on clinical practice, especially in developing countries. It may provide a better understanding of MAFLD, and optimize strategies for prevention of extrahepatic complications in clinical practice.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTthe differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

Timeline

Start date
2012-01-01
Primary completion
2019-12-31
Completion
2020-12-31
First posted
2021-02-21
Last updated
2021-02-21

Source: ClinicalTrials.gov record NCT04761900. Inclusion in this directory is not an endorsement.